Leading the Establishment of New Standards in Clinical Trial Data ManagementC&R Research announced on the 30th that it successfully held its second webinar under the theme, 'LNR(Lab Normal Range) Mastery: From Raw Data to Reliable Insights’.LNR is an essential element that impacts all stages of clinical trials, including adverse event assessment and drug safety interpretation. With growing emphasis on clinical data quality and safety analysis, this webinar attracted significant attention across its key topics.During the webinar, Heoncheol Ha, Data Management 1 Team Manager, presented 'Collect it Right: Error Prevention in Lab Normal Range Collection', while Jinseok Kim, Data Management 3 Team Manager, delivered a talk titled 'Beyond Collection: Lab Normal Range Quality Management'.  Read the text | 출처: Yakup News

   Initiation of the FDA Pre-IND consultation process in collaboration with C&R ResearchEnsol Biosciences has initiated the FDA Pre-IND consultation process to assess the feasibility of a U.S. Phase 3 clinical trial for its osteoarthritis treatment candidate, E1K (Engedi1000). The candidate is currently under Phase 3 IND review by the MFDS.To support and strengthen its global clinical and regulatory strategy, Ensol Biosciences is working closely with C&R Research, Inc, which is providing comprehensive CRO expertise throughout the preparation.C&R Research, Inc is providing strategic oversight and guidance, with the goal of receiving FDA feedback in the first half of next year.  Read the text | Ref: Biz Watch

   C&R Research (CEO Moontae Yoon) announced today that it will hold its second webinar on October 29th. The webinar, titled 'LNR (Lab Normal Range) Mastery: From Raw Data to Reliable Insights,' will provide an in-depth, integrated guide for the proper collection and application of Lab data in clinical trials.LNR is essential for safety evaluation and ensuring data reliability in clinical trials, but it carries a high risk of errors, particularly in long-term, multi-center studies. This webinar will predict potential errors that can occur during the data collection process and propose practical quality control strategies applicable to real-world scenarios.The webinar will consist of two main sessions:In the first session, Heoncheol Ha, Team Leader 1 of Data Management at C&R Research's Information Division, will present 'Collect it Right: Error Prevention in Lab Normal Range Collection'. This session will introduce solutions aimed at minimizing errors during the LNR collection phase.In the second session, Jinseok Kim, Team Leader 3, will discuss 'Beyond Collection: Quality Management & Regulatory Alignment'. He will analyze the risks associated with applying LNR to EDC (Electronic Data Capture), propose standardized management strategies, and present effective management methods through real-world case studies.Sookjung Jo, Vice President of C&R Research's Information Division, stated, "This webinar will offer practical solutions to systematically resolve the difficulties in LNR management. We believe it will provide clinical professionals with valuable insights and enhance their practical competitiveness through our differentiated strategies and real-world application cases."The webinar is free and registration is available through the official C&R Research website. Pre-registration is open until the 24th of this month. Access links will be sent individually via email to pre-registered attendees.  Read the text | Pharmnews

   Strengthen your strategic partner status  C&R Research announced on the 26th that it successfully concluded the event with differentiated expertise and on-site communication at Asia's largest clinical conference "2025 Conference on International Clinical Trials (KIC)."KIC, which marks its 11th anniversary this year, held various programs such as conferences and exhibitions under the theme of "Innovation of Clinical Trials through Technology, Diversity, and Cooperation," and more than 1,500 people, including bio and clinical experts, participated in the event from 20 countries around the world.Through the operation of the booth, C&R Research focused the attention of clinical industry officials such as pharmaceutical companies, biotech companies, and hospitals. At this meeting, we exchanged the core capabilities of C&R Research for integrated whole-cycle clinical services and discussed in-depth partnering with participants to explore the possibility of future cooperation.In addition, we conducted a joint survey with family members (GCCL, Trial Informatics, TI Image, C&R SMO, and ABC Bioscience) on the overall organically connected pre-cycle services. It received great response as a place to identify the needs of the industry and listen to the voices of participants.In particular, the presentation session presented by C&R Research at this KIC presented a key strategy to look at the future of new drug development by conducting under the themes of innovative statistical design techniques of early clinical trials (Sookjung Jo, Vice President), Korea's global clinical trial hub background and know-how of C&R (Yunho Kim, Executive Director) and DSUR strategic use of new drug development (Hwang So-yeon, Part Manager)."This KIC is an important place to broaden the horizon of cooperation by sharing C&R Research's overall clinical trial strategy and rich global experience," said Moontae Yoon, CEO of C&R Research. "We will use this as a stepping stone to solidify our position as a strategic partner with domestic and foreign pharmaceutical bio companies and grow as a strong partner in new drug development." Read the text | Hankyung

  The only CRO company to participate...Emphasis on the core competitiveness of the bio industryC&R Research, a Contract Research Organization (CRO), announced on the 17th that it was the only CRO company to participate in the 'Korea Investment Week (KIW) 2025', the largest investment event in Korea, on the 16th and made a presentation under the theme of 'Strategy to Maximize Clinical Trial Efficiency'.This year's event was held at the Conrad Seoul Hotel under the theme of "KOSPI 5000, Age of Daejeon Transformation," highlighting key industries that will lead to long-term stock market growth. In particular, the bio-industry drew attention in terms of high value-added industries and technological innovation potential, and CRO-related sessions were organized.In a clinical trial environment where regulations are recently strengthened, CRO is evolving beyond simple consignment agencies to become a strategic partner in new drug development. CRO's expertise in integrating the entire clinical trial process and leading collaboration among stakeholders is evaluated as a key factor for the success of new drug development."The government's large-scale R&D investment is boosting candidate development and overseas expansion," said Kim Jinhak Kim, head of C&R Research's U.S. subsidiary. "As a result, demand for clinical trials is expected to continue to increase, maximizing the efficiency of new drug development is an important competitiveness of the bio industry."C&R Research has advanced clinical trial innovation based on its global network and professional capabilities, he said. "We are ready to take off with the industry to strengthen international competitiveness in the future." Read the text | Pharmnews       

    CRO C&R Research, which specializes in clinical trials, announced on the 9th that it will be a three-session speaker at the "2025 KIC" held at Lotte Hotel in Jung-gu, Seoul for three days from the 22nd to the 24th.Through this lecture, we will share innovation strategies across clinical trials, from initial clinical statistics to safety management and global clinical performance know-how, and share innovation achievements in global clinical trials.Cho Sook-jung, vice president of the Intelligence Headquarters, will give a lecture on 'Statistical Innovation in Early Stage Clinical Trials'. In this lecture, we will introduce innovative statistical design techniques to establish an optimal dose range that is safe and effective in the early clinical stage. This is expected to serve as an opportunity to raise awareness of the importance of early clinical trials in the new drug development process.Kim Yoon-ho, managing director of the business division, will present the theme of "Cost-Effective Global Trials: What We Learned After Execution." We will introduce C&R Research's global clinical strategy and know-how through real-world examples along with the background of Korea becoming a global clinical trial hub.Hwang So-yeon, the head of the information division, will give a lecture on Development Safety Update Reports (DSUR): Role, Strategic Applications, and Key Considers. It introduces the role of DSUR in the development of new drugs and key considerations when writing them, and deals with how pharmaceutical companies can strategically use DSUR based on their actual experiences.In addition, C&R Research will strengthen on-site communication by introducing its capabilities as a CRO specializing in global clinical trials through a promotional booth.  Read the text | Medipana